I joined Genentech in 2004 as part of Research Drug Discovery, and am currently Senior Director of the Translational Oncology department. I was attracted to Genentech because of the palpable commitment to helping patients by drawing on scientific insights.

• My Focus

  The research in my department includes validation of oncology targets in intracellular signaling pathways, investigation of signaling networks, understanding mechanism of action of compounds, pharmacology, discovery and validation of preclinical PD assays, and predicting which patients will respond to new agents.

  We work closely with groups throughout the company, including other departments in Research, Development Sciences, and Clinical. In addition we collaborate with a variety of external partners on drug discovery projects.

• Publications

  • Systems-wide analysis of K-Ras, Cdc42 and PAK4 signaling by quantitative phosphoproteomics

    Molecular and Cellular Proteomics, 2013, ISSN: 1535-9476

    Gnad, Florian; Young, Amy; Zhou, Wei; Lyle, Karen; Ong, Christy C; Stokes, Matthew P; Silva, Jeffrey C; Belvin, Marcia; Friedman, Lori S; Koeppen, Hartmut; Minden, Audrey; Hoeflich, Klaus

     View on PubMed

  • Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR)

    Journal of Medicinal Chemistry, 2013, ISSN: 0022-2623

    Estrada, Anthony A; Shore, Daniel G; Blackwood, Elizabeth; Chen, Yung-Hsiang; Deshmukh, Gauri; Ding, Xiao; Dipasquale, Antonio G; Epler, Jennifer A; Friedman, Lori S; Koehler, Michael F T; Liu, Lichuan; Malek, Shiva; Nonomiya, Jim; Ortwine, Daniel F; Pei, Zhonghua; Sideris, Steve; St-Jean, Frederic; Trinh, Lan; Truong, Tom; Lyssikatos, Joseph P

     View on PubMed

  • Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models

    Clinical Cancer Research, 2013, ISSN: 1078-0432

    Lin, Jie; Sampath, Deepak; Nannini, Michelle A; Lee, Brian B; Degtyarev, Michael; Oeh, Jason; Savage, Heidi; Guan, Zhengyu; Hong, Rebecca; Kassees, Robert; Lee, Leslie B; Risom, Tyler; Gross, Stefan D; Liederer, Bianca; Koeppen, Hartmut; Skelton, Nicholas; Wallin, Jeffrey J; Belvin, Marcia; Punnoose, Elizabeth A; Friedman, Lori S; Lin, Kui

     View on PubMed

  • A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal

    Clinical Cancer Research, 2012, ISSN: 1078-0432

    Floris, Giuseppe; Wozniak, Agnieszka; Sciot, Raf; Li, Haifu; Friedman, Lori; Van Looy, Thomas; Wellens, Jasmien; Vermaelen, Peter; Deroose, Christophe M; Fletcher, Jonathan A; Debiec-Rychter, Maria; Schöffski, Patrick

     View on PubMed

  • Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349

    ACS Medicinal Chemistry Letters, 2012, ISSN:

    Pei, Zhonghua; Blackwood, Elizabeth; Liu, Lichuan; Malek, Shiva; Belvin, Marcia; Koehler, Michael F. T.; Ortwine, Daniel F.; Chen, Huifen; Cohen, Frederick; Kenny, Jane R.; Bergeron, Philippe; Lau, Kevin; Ly, Cuong; Zhao, Xianrui; Estrada, Anthony A.; Truong, Tom; Epler, Jennifer A.; Nonomiya, Jim; Trinh, Lan; Sideris, Steve; Lesnick, John; Bao, Linda; Vijapurkar, Ulka; Mukadam, Sophie; Tay, Suzanne; Deshmukh, Gauri; Chen, Yung-Hsiang; Ding, Xiao; Friedman, Lori S.; Lyssikatos, Joseph P.

     View on PubMed

  • Phosphoinositide 3-kinase (PI3K) Pathway Alterations are Associated with Histologic Subtypes and are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

    Clinical Cancer Research, 2012, ISSN: 1078-0432

    Spoerke, Jill M; O'Brien, Carol; Huw, Ling; Koeppen, Hartmut; Fridlyand, Jane; Brachmann, Rainer; Haverty, Peter M; Pandita, Ajay; Mohan, Sankar; Sampath, Deepak; Friedman, Lori S; Ross, Leanne; Hampton, Garret M; Amler, Lukas C; Shames, David S; Lackner, Mark R

     View on PubMed

  • mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations

    Cancer Letters, 2012, ISSN: 0304-3835

    Vijapurkar, Ulka; Robillard, Liliane; Zhou, Siqun; Degtyarev, Michael; Lin, Kui; Truong, Tom; Tremayne, Jarrod; Ross, Leanne Berry; Pei, Zhonghua; Friedman, Lori S; Blackwood, Elizabeth M; Belvin, Marcia

     View on PubMed

  • Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response

    Clinical Cancer Research, 2012, ISSN: 1078-0432

    Wong, Harvey; Choo, Edna F.; Alicke, Bruno; Ding, Xiao; La, Hank; McNamara, Erin; Theil, Frank-Peter; Tibbitts, Jay; Friedman, Lori S.; Hop, Cornelis E. C. A.; Gould, Stephen E.

     View on PubMed

  • Anti-tumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.

    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, ISSN: 1078-0432

    Wong, Harvey; Choo, Edna F; Alicke, Bruno; Ding, Xiao; La, Hank; McNamara, Erin; Theil, Frank-Peter; Tibbitts, Jay; Friedman, Lori S; Hop, Cornelis Eca; Gould, Stephen E

  • GDC-0941, A Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

    Clinical Cancer Research, 2012, ISSN: 1078-0432

    Wallin, Jeffrey J; Guan, Jane; Prior, Wei Wei; Lee, Leslie B; Berry, Leanne; Belmont, Lisa D; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S; Sampath, Deepak;

     View on PubMed

  • ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

    Molecular Cancer Therapeutics, 2012, ISSN: 1535-7163

    Hatzivassiliou, Georgia; Liu, Bonnie; O'Brien, Carol; Spoerke, Jill M; Hoeflich, Klaus P; Haverty, Peter M; Soriano, Robert; Forrest, William F; Heldens, Sherry; Chen, Huifen; Toy, Karen; Ha, Connie; Zhou, Wei; Song, Kyung; Friedman, Lori S; Amler, Lukas C; Hampton, Garret M; Moffat, John; Belvin, Marcia; Lackner, Mark R;

     View on PubMed

  • An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt

    Science Signaling, 2012, ISSN: 1937-9145

    Lin, Kui; Lin, Jie; Wu, Wen-I; Ballard, Joshua; Lee, Brian B.; Gloor, Susan L.; Vigers, Guy P. A.; Morales, Tony H.; Friedman, Lori S.; Skelton, Nicholas; Brandhuber, Barbara J. ;

     View on PubMed

  • Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes

    PLoS ONE, 2012, ISSN: 1932-6203

    Wallin, Jeffrey J; Guan, Jane; Edgar, Kyle A; Zhou, Wei; Francis, Ross; Torres, Anthony C; Haverty, Peter M; Eastham-Anderson, Jeffrey; Arena, Sabrina; Bardelli, Alberto; Griffin, Sue; Goodall, John E; Grimshaw, Kyla M; Hoeflich, Klaus P; Torrance, Christopher; Belvin, Marcia; Friedman, Lori S

     View on PubMed

  • Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

    Cancer Cell, 2011, ISSN: 1535-6108

    Junttila, Teemu T.; Akita, Robert W.; Parsons, Kathryn; Fields, Carter; Lewis Phillips, Gail D.; Friedman, Lori S.; Sampath, Deepak; Sliwkowski, Mark X.

     View on PubMed

  • GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.

    Molecular Cancer Therapeutics, 13 Oct 2011, ISSN: 1538-8514.

    Wallin, Jeffrey J; Edgar, Kyle A; Guan, Jane; Berry, Megan; Prior, Wei Wei; Lee, Leslie; Lesnick, John D; Lewis, Cristina; Nonomiya, Jim; Pang, Jodie; Salphati, Laurent; Olivero, Alan G; Sutherlin, Daniel P; O, Brien Carol; Spoerke, Jill M; Patel, Sonal; Lensun, Letitia; Kassees, Robert; Ross, Leanne; Lackner, Mark R; Sampath, Deepak; Belvin, Marcia; Friedman, Lori S

     View on PubMed

  • Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (m TOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer.

    Journal of Medicinal Chemistry, 7 Oct 2011, ISSN: 1520-4804.

    Sutherlin, Daniel P; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Binqing; Wiesmann, Christian; Wu, Ping; Zhu, Bing Yan; Olivero, Alan

     View on PubMed

  • p21-activated kinase 1: PAK'ed with potential.

    Oncotarget, {Oncotarget}, 7 Jun 2011 (epub: 7 6 2011), ISSN: 1949-2553.

    Ong, Christy C; Jubb, Adrian M; Zhou, Wei; Haverty, Peter M; Harris, Adrian L; Belvin, Marcia; Friedman, Lori S; Koeppen, Hartmut; Hoeflich, Klaus P

  • Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer.

    Science Translational Medicine, 2010, ISSN:

    Wallin, J.J.; Guan, J.; Prior, W.W.; Edgar, K.A.; Kassees, R.; Sampath, D.; Belvin, M.; Friedman, L.S.

  • PI3K inhibitors prime neuroblastoma cells for chemotherapy in vitro and in vivo: A novo strategy to reactivate the mitochondrial pathway of apoptosis.

    Onkologie, 2010, ISSN: 0378-584X

    Bender, A.; Naumann, I.; Opel, D.; Kappler, R.; Friedman, L.; von Schweinitz, D.; Debatin, K.M.; Fulda, S.

  • Mutant PIK3CA increases the expression of individual tubulin isoforms and promotes resistance to anti-mitotic chemotherapy drugs.

    Proceedings of the American Association for Cancer Research Annual Meeting, 2010, ISSN: 0197-016X

    Wallin, J.; Guan, J.; Xiao, Y.; O'Brien, T.; Belvin, M.; Friedman, L.

  • P21-activated kinase-1 (PAK1) as a therapeutic target in cancer.

    Proceedings of the American Association for Cancer Research Annual Meeting, 2010, ISSN: 0197-016X

    Ong, C.; Jubb, A.; Truong, T.; Zhou, W.; Tran, V.; Haverty, P.; Turley, H.; Vucic, D.; Belvin, M.; Blackwood, E.; Harris, A.; Friedman, L.; Koeppen, H.; Hoeflich, K.

  • PI3K inhibitor GDC-0941 synergizes with mTOR inhibitors by blocking negative feedback and causes distinct effects on signaling and apoptosis compared to a dual PI3K/mTOR inhibitor.

    Proceedings of the American Association for Cancer Research Annual Meeting, 2010, ISSN: 0197-016X

    Vijapurkar, U.; Robillard, L.; Friedman, L.; Belvin, M.

  • Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer.

    Science Translational Medicine, 2010, ISSN: 1946-6242

    Wallin, J.; Guan, J.; Prior, W.-W.; Edgar, K.; Kassees, R.; Sampath, D.; Belvin, M.; Friedman, L.

  • Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.

    Bioorganic & Medicinal Chemistry Letters, 2010, ISSN: 1464-3405

    Staben, S.; Heffron, T.; Sutherlin, D.; Bhat, S.; Castanedo, G.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Lee, L.; Lesnick, J.; Lewis, C.; Murray, J.; Nonomiya, J.; Olivero, A.; Plise, E.; Pang, J.; Prior, W.-W.; Salphati, L.; Rouge, L.; Sampath, D.; Tsui, V.; Wan, N.C.; Wang, S.; Weismann, C.; Wu, P.; Zhu, B.-Y.

  • Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models.

    Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2010, ISSN: 1078-0432

    O'Brien, C.; Wallin, J.; Sampath, D.; Guhathakurta, D.; Savage, H.; Punnoose, E.; Guan, J.; Berry, L.; Prior, W.-W.; Amler, L.; Belvin, M.; Friedman, L.; Lackner, M.

  • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

    Nature, 2010, ISSN: 1476-4687

    Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K.P.; Jaiswal, B.S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L.S.; Malek, S.

  • Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

    Journal of Medicinal Chemistry, 2010, ISSN: 1520-4804

    Sutherlin, D.P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R.; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W.W.; Salphati, L.; Sideris. S.; Tian, Q.; Tsui, V.; Wan, N.C.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B.Y.

  • Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors.

    Cancer Research, 2010, ISSN: 1538-7445

    Edgar, K.A.; Wallin, J.J.; Berry, M.; Lee, L.B.; Prior, W.W.; Sampath, D.; Friedman, L.S.; Belvin, M.

  • Identifying genotype-dependent efficacy of single and combined P13K- and MAPK-pathway inhibition in cancer.

    Proc. Natl. Acad. Sci. USA, 2009, ISSN: 0027-8424

    Sos, M.L.; Fischer, S.; Ullrich, R.; Peifer, M.; Heuckmann, J.M.; Koker, M.; Heynck, S.; Stuckrath, I.S; Weiss, J.; ....Shokat, K.M.; Sellers, W.R.; Rauh, D.; Orr, C.; Hoeflich, K.P.; Friedman, L.; Wong, K.-K.; Pao, W.; Thomas, R.K.

  • Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

    Clinical Cancer Research, 2009, ISSN: 1078-0432

    Yao, E.; Zhou, W.; Lee-Hoeflich, S.T.;Truong T.; Haverty, P.M.;Eastham-Anderson, J.; Lewin-Koh, N.; Gunter, B.; Belvin, M.; Murray, L.J.; Friedman, L.S.; Sliwkowski, M.X.; Hoeflich, K.P.

  • Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

    Cancer Cell, 2009, ISSN: 1535-6108

    Junttila, T.T.; Akita, R.W.; Parsons, K.; Fields, C.; Lewis Phillips, G.D.; Friedman, L.S.; Sampath, D.; Sliwkowski, M.X.

  • Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAF^V600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

    Cancer Research, 2009, ISSN: 1538-7445

    Hoeflich, K.P.; Herter, S.; Tien, J.; Wong, L.; Berry, L.; Chan, J.; O'Brien, C.; Modrusan, Z.; Seshagiri, S.; Lackner, M.; Stern, H.; Choo, E.; Murray, L.; Friedman, L.S.; Belvin, M.

• Education
  • Cambridge University, England, Postdoctoral Fellow – 1998
  • University of Washington, Seattle, Postdoctoral Fellow – 1995
  • University of California, Berkeley, Molecular and Cell Biology, Ph.D – 1995
  • University of Iowa, Microbiology, B.S. – 1986
• Awards & Honors
  • Hitchings-Elion Fellow, Burroughs Wellcome Fund – 1998
  • Sigrid Juselius Foundation Visiting Scientist – 1995
  • Susan G. Komen Breast Cancer Foundation Fellow – 1995
  • Clare Booth Luce Fellowship, – 1991